Combined oral and topical mesalazine treatment for extensive ulcerative colitis

Nat Clin Pract Gastroenterol Hepatol. 2006 May;3(5):290-3. doi: 10.1038/ncpgasthep0475.

Abstract

Background: A 32-year-old white Jewish woman was referred to our clinic in October 2002 for a second opinion on the management of her active extensive ulcerative colitis that did not respond to oral mesalazine (mesalamine) 3.6 g/day. The severity of symptoms had affected her plans to have children.

Investigations: Laboratory investigations, including perinuclear antineutrophil cytoplasmic antibodies and antibodies to Saccharomyces cerevisiae, stool cultures, and sigmoidoscopy to 40 cm from the rectum, with biopsies.

Diagnosis: Moderate-to-severe active extensive ulcerative colitis, unresponsive to mesalazine at 3.6 g/day.

Management: Oral mesalazine 4.8 g/day and 4 g mesalazine enemas nightly.

Publication types

  • Case Reports

MeSH terms

  • Administration, Oral
  • Administration, Topical
  • Adult
  • Anti-Inflammatory Agents, Non-Steroidal / administration & dosage*
  • Colitis, Ulcerative / drug therapy*
  • Enema
  • Female
  • Humans
  • Mesalamine / administration & dosage*
  • Pregnancy
  • Pregnancy Complications / drug therapy*

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Mesalamine